Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c6ee3cf6-e031-4d9a-9b2a-45da9e9b9e12
Date 7/19/2016
Company Name Neurovance
Mailing Address 43 Thorndike Street Cambridge, MA 02141 USA
Company Description Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD.
Proceeds Purposes Proceeds purposes were not disclosed. 7 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.